NCT00096434View on ClinicalTrials.gov

Sorafenib in Treating Patients With Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

June 30, 2006

Conditions
Male Breast CancerRecurrent Breast CancerStage IV Breast Cancer
Interventions
DRUG

sorafenib tosylate

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

55905

North Central Cancer Treatment Group, Rochester

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00096434 - Sorafenib in Treating Patients With Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter